Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori

Takahisa Furuta; Mihoko Yamade; Tomohiro Higuchi; Satoru Takahashi; Natsuki Ishida; Shinya Tani; Satoshi Tamura; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Ken Sugimoto

doi:10.3390/jcm12093110

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori

J Clin Med. 2023 Apr 25;12(9):3110. doi: 10.3390/jcm12093110.

Authors

Affiliations

¹ Furuta Clinic for Internal Medicine, 1963-15 Mitsuke, Iwata, Shizuoka 438-0086, Japan.
² First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.
³ Clinical Laboratories, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.
⁴ Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan.

Abstract

Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.

Keywords: H. pylori; amoxicillin (AMOX); clarithromycin (CAM); dual therapy; vonoprazan (VPZ).

Publication types

Review

Grants and funding

This research received no external funding.